2. Disease Areas
  3. Musculoskeletal Disease
  4. Osteogenic Differentiation

Osteogenic Differentiation

Osteogenic differentiation is the process by which multipotent stem cells commit to an osteogenic lineage and mature into osteogenic cells essential for bone regeneration, regulated by a combination of biochemical growth factors and physical cues that promote proliferation and lineage-specific differentiation.

Osteogenic Differentiation (11):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-Y1353
    Di-tert-butyl dicarbonate 24424-99-5 99.77%
    Di-tert-butyl dicarbonate (tBOC) is a covalent modification agent for hydroxyl groups (-OH) on the chitosan molecular chain. Di-tert-butyl dicarbonate selectively modifies chitosan and stabilizes the material structure through hydrophobic encapsulation. Di-tert-butyl dicarbonate reacts with the -OH groups of chitosan to form a hydrophobic layer, and in conjunction with triethylamine (TEA), removes trifluoroacetic acid (TFA) salts produced during the electrospinning process, preserving the nanofiber structure and high porosity of the membrane, and improving the material's cytocompatibility and mineralization-promoting ability. Di-tert-butyl dicarbonate can be used in research in the field of guided bone regeneration (GBR).
    Di-tert-butyl dicarbonate
  • HY-106950
    Fosfructose 488-69-7 98.0%
    Fosfructose is an orally active cyclooxygenase-2 inhibitor and Toll-like receptor 4 modulator. Fosfructose reduces the expression of cyclooxygenase-2, thereby decreasing prostaglandin production. By inhibiting the Toll-like receptor 4 signaling pathway, Fosfructose downregulates LPS-induced adhesion molecule expression. Fosfructose is applicable to research related to ischemic stroke, epilepsy, sepsis, myocardial injury, osteoporosis, and ultraviolet B-induced skin damage.
    Fosfructose
  • HY-P5832
    BMP2-derived peptide 836606-84-9 98.04%
    BMP2-derived peptide is an osteogenic inducer and BMP receptor ligand. BMP2-derived peptide binds to BMP receptors on the cell surface to form a complex, activates the downstream Smad signaling pathway, and regulates the expression of osteogenic transcription factors. BMP2-derived peptide effectively promotes the adhesion, proliferation, osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells, significantly up-regulates the mRNA levels of OCN, Runx2 and type I collagen, and increases alkaline phosphatase activity and calcium deposition. BMP2-derived peptide induces osteoblast differentiation and ectopic bone regeneration, and improves cranial bone defect repair. Meanwhile, BMP2-derived peptide enhances the cytocompatibility of mesoporous silica nanoparticles, synergistically increases osteogenic activity with Dexamethasone (HY-14648), serving as an important tool for bone defect repair research.
    BMP2-derived peptide
  • HY-119443
    Neridronate 79778-41-9 98.0%
    Neridronate is an aminobisphosphonate. Neridronate induces osteoblast differentiation, enhances alkaline phosphatase activity and mineralized nodule formation. Neridronate inhibits endothelial cell proliferation, fibroblast growth factor-2-induced capillary-like tube formation, and angiogenesis. Neridronate can be used for osteogenesis imperfecta and Paget’s disease of bone.
    Neridronate
  • HY-103322
    6-Bnz-cAMP sodium salt 1135306-29-4 98.5%
    6-Bnz-cAMP sodium, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K+ channel. 6-Bnz-cAMP sodium does not activate the Epac signaling pathway. It inhibits the bTREK-1 K+ channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP sodium activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. It can be used in studies related to bone tissue repair and regeneration.
    6-Bnz-cAMP sodium salt
  • HY-W115785
    Zinc borate 1332-07-6
    Zinc borate is a bioactive inorganic substance with properties including osteogenic induction, pro-angiogenesis, antioxidation, antimutagenesis and cytotoxicity. In the field of bone tissue engineering, Zinc borate is often incorporated into chitosan scaffolds. By releasing zinc ions and borate ions, Zinc borate induces the differentiation of human dental pulp stem cells into osteoblasts, upregulates the expression of bone-related genes and promotes calcium deposition. Zinc borate also promotes angiogenesis by upregulating key factors such as vascular endothelial growth factor. Zinc borate exhibits antioxidant capacity to scavenge free radicals, and can specifically reduce mutagenicity under specific conditions. Zinc borate reduces the survival rate of mouse fibroblasts, but it can still be used in studies related to bone tissue engineering.
    Zinc borate
  • HY-114159
    GGTI-2166 478908-51-9
    GGTI-2166 is a geranylgeranyltransferase I (GGTase I) inhibitor. GGTI-2166 blocks geranylgeranylation modification of target proteins. GGTI-2166 inhibits RANKL- or TNF-α-induced pre-osteoclast formation and TRAP activity. GGTI-2166 is applicable to research on osteoclast differentiation.
    GGTI-2166
  • HY-178899
    C14-Tri-LAN-Gly 1863978-69-1
    C14-Tri-LAN-Gly is a highly selective and potent NOD1 agonist. C14-Tri-LAN-Gly activates NOD1. C14-Tri-LAN-Gly inhibits the expression of cleaved-caspase3. C14-Tri-LAN-Gly upregulates A20 expression. C14-Tri-LAN-Gly protects mice from lethal hepatitis by inhibiting hepatocyte Apoptosis. C14-Tri-LAN-Gly inhibits osteoblastogenesis and promots osteoclastogenesis.
    C14-Tri-LAN-Gly
  • HY-100428
    Netoglitazone 161600-01-7 99.92%
    Netoglitazone (MCC-555) is an orally active PPARγ ligand with an EC50 of 8 μM. Netoglitazone mediates cell type-specific functional regulation, and modulates the transcriptional activity of PPARγ as a full agonist, partial agonist or antagonist. Netoglitazone induces adipogenesis, inhibits osteoblastogenesis, alters the weight of extramedullary fat depots and enhances insulin sensitivity. Netoglitazone reduces blood glucose levels. Netoglitazone can be used in research related to type 2 diabetes and non-insulin-dependent diabetes mellitus.
    Netoglitazone
  • HY-W019901B
    Anhydrous calcium sulfate (97%) 7778-18-9 99.40%
    Anhydrous calcium sulfate (97%) serves as an oil-based drilling fluid additive and an osteogenic material. Anhydrous calcium sulfate (97%) increases the plastic viscosity, yield point, apparent viscosity and gel strength of oil-based drilling fluids. Anhydrous calcium sulfate (97%) upregulates the expression of bone-related genes FOSL1, RUNX2 and SPP1. Anhydrous calcium sulfate (97%) significantly affects the behavior of dental pulp stem cells, enhancing their proliferation, differentiation and matrix deposition.
    Anhydrous calcium sulfate (97%)
  • HY-137381
    6-Bnz-cAMP 30275-80-0
    6-Bnz-cAMP, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K+ channel. 6-Bnz-cAMP does not activate the Epac signaling pathway. 6-Bnz-cAMP inhibits the bTREK-1 K+ channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. 6-Bnz-cAMP can be used in studies related to bone tissue repair and regeneration.
    6-Bnz-cAMP